🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-520790-39-00
Completed Phase I

CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)

2025-520790-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Universitaetsklinikum Heidelberg AöR
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Immune System Diseases
Decision date
25/11/2025
Enrollment target
7
Sites
Germany

Condition studied

relapsed or refractory AL amyloidosis

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-520790-39-00 on CTIS ↗ ← All trials in the EU